Differential Inhibitory Actions of Multitargeted Tyrosine Kinase Inhibitors on Different Ionic Current Types in

Wei-Ting Chang1,2,3, Ping-Yen Liu1,4, Kaisen Lee5

  • 1Institute of Clinical Medicine, College of Medicine, National Cheng Kung University, Tainan 70101, Taiwan.

Insights

Lapatinib (LAP) and sorafenib (SOR), tyrosine kinase inhibitors (TKIs), prolong QTc intervals by suppressing cardiac ion channel activity, particularly the slowly activating delayed-rectifier K+ current (IK(S)). This mechanism underlies their cardiotoxicity.

Area of Science:

  • Cardiology
  • Pharmacology
  • Molecular Biology

Background:

  • Lapatinib (LAP) and sorafenib (SOR) are multitargeted tyrosine kinase inhibitors (TKIs) with antineoplastic properties.
  • Clinical observations suggest LAP and SOR may cause QTc prolongation, but the underlying mechanisms remain largely uninvestigated.

Purpose of the Study:

  • To investigate the effects of LAP and SOR on membrane ion channel activities.
  • To elucidate the detailed mechanism by which LAP and SOR induce QTc prolongation.

Main Methods:

  • Utilized a small animal model and primary cardiomyocytes to study the impact of LAP and SOR on Na+ and K+ currents.
  • Examined the effects of LAP and SOR on the slowly activating delayed-rectifier K+ current (IK(S)) in H9c2 cells.
  • Investigated the influence of LAP and SOR on inwardly rectifying K+ and voltage-gated Na+ currents in neonatal rat ventricular myocytes.

Main Results:

  • LAP-induced QTc prolongation in mice was reversible by isoproterenol.
  • LAP and SOR suppressed the amplitude of IK(S) in a time- and concentration-dependent manner, shifting its activation curve towards less negative potentials.
  • LAP and SOR also inhibited inwardly rectifying K+ and voltage-gated Na+ currents in cardiomyocytes.

Conclusions:

  • LAP and SOR suppress key cardiac ion currents, including IK(S), contributing to QTc interval prolongation.
  • The inhibition of these ionic currents represents a significant mechanism underlying the cardiotoxicity associated with these TKIs.

Related Concept Videos

Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers01:12

Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers

Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of...
1.7K
Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers01:22

Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers

Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
2.6K
Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers01:20

Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers

Class IV antiarrhythmic drugs, such as verapamil and diltiazem, block calcium channels. They primarily affect the heart, slowing the conduction in calcium-dependent tissues like the SA and AV nodes. These drugs manage reentrant supraventricular tachycardia (SVT) and reduce ventricular rate in atrial flutter/fibrillation.
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
1.4K
Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
1.1K
Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers01:24

Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers

Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which...
1.3K
Depolarizing Blockers: Mechanism of Action01:28

Depolarizing Blockers: Mechanism of Action

Depolarizing blockers act on skeletal muscle fibers' membranes and induce their depolarization. Most depolarizing blockers have two quaternary N+ atoms that bind the nicotinic acetylcholine receptors and cause neuromuscular blockade within minutes.
Succinylcholine is the most commonly used depolarizing blocker. Chemically, it constitutes two molecules of acetylcholine joined together by an acetate methyl group. They act on the receptors in the same way as acetylcholine. Because...
2.5K